1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

20 Mar 2024
Admin
News Article

Sun Pharma Receives Australian TGA Approval for Winlevi

Sun Pharma receives Australian TGA approval for Winlevi to treat acne vulgaris in patients 12 years of age and older

Overview

Sun Pharmaceutical Industries Limited announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for Winlevi (clascoterone cream 1%). Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

Words from Sun Pharma Leaders

As stated by Hellen de Kloet, business head – Western Europe, Australia and New Zealand, Sun Pharma “Winlevi is an exciting addition to our expanding dermatology portfolio of innovative medicines in Australia. Winlevi’s novel mechanism of action will be a welcome addition to the physician’s toolkit while treating acne.”
Diana Harbort, president of the dermatology division of Cosmo, said: “We are very pleased that Winlevi will soon be available to patients in Australia. This is another achievement in the mission of Cosmo and Sun Pharma to improve the lives of patients affected by skin conditions.”

Availability- According to a company press release, Winlevi will be available in Australia by this June.

Indication and Mechanism

Winlevi is approved for the topical treatment of acne vulgaris in people 12 years of age and older.
Although the exact mechanism of action for Winlevi is unknown, laboratory studies suggest the active ingredient, clascoterone, competes with androgens, specifically dihydrotestosterone (DHT), for binding to the androgen receptors within the sebaceous gland and hair follicles.

About Androgens

Androgens are widely recognized as the most important of all hormones in terms of regulating sebum production.
Within the skin, androgens bind to androgen receptors, causing increased sebum production and inflammation.
In particular, the skin of patients with acne vulgaris produces higher levels of the androgens testosterone and dihydrotestosterone (DHT) than the skin of healthy individuals.

Winlevi: MOA

Winlevi binds to the androgen receptor competing with androgens such as DHT on cells within the sebaceous gland.
Although its precise mechanism of action is unknown, studies suggest Winlevi inhibits androgen receptors5 in the skin and reduces production of sebum and inflammation.
Additionally, Winlevi is rapidly metabolized in the skin, limiting systemic absorption.

Other Exclusive Rights

Sun Pharma has received from Cosmo the exclusive right to develop and commercialize Winlevi in US, Japan, Australia, New Zealand, Brazil, Mexico and Russia.

About Sun Pharma

Sun Pharma is the world’s fourth largest specialty generics company with presence in specialty, generics and consumer healthcare products.
It is the largest pharmaceutical company in India, and is a leading generic company in the US as well as global emerging markets.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!